Clinical Trial Update: The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effects of Nexium (esomeprazole) and probiotics on insulin secretion and cardiovascular risk factors in Type 2 diabetes. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Nexium (esomeprazole)
• Probiotics

Snippet

Sponsor: Lise Tarnow | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED